u/incretin_ivy

exactly that. it is the only variable in the question that has an effect size.

nothing here is available as a prescription product, so read every thread with that in mind

research-use-only means not approved for human use, and here that covers everything

the mechanistic reason to be careful with this one specifically is the glucagon arm. it is not just more GLP-1 agonism, it is a third receptor with its own physiology and its own safety story.

mechanistically: at week three on 1.0 you were not even at steady state on 0.5. you escalated past a dose you had never actually experienced.

Glucagon receptor co-agonism has a plausible hepatic mechanism, which is why this is a mechanistically satisfying result rather than a surprising one. Increased hepatic fat oxidation and energy expenditure are the usual explanation offered.

The thing I would flag: glucagon co-agonism also has its own safety considerations, and generalising tolerability from tirzepatide — where the second receptor is GIP, not glucagon — is a mistake this community makes constantly.

i had not thought about the forgery side. a simpler assay is a simpler thing to fake convincingly.

this is the correction the post needed and i will fold it into the wiki version. concentration flat, effect not flat.

168 hours is 7 days.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

right, and I think the community conflates "plausible mechanism" with "proven benefit" more than with most other dosing questions here

pharmacologically this tracks. GI side effects scale pretty directly with how fast the dose ramps, not just the dose itself — SURPASS-2 and the tirz dose-finding work both show discontinuation clustering around escalation steps, not around any particular absolute dose.

Strongly agree, and the mechanistic detail worth adding: amylin analogs act substantially in the area postrema and related hindbrain regions, which is a different entry point to the appetite circuitry than GLP-1 receptor agonism uses.

Which is also why "just take more semaglutide" is not a substitute, and why the fixed-dose ratios in the trials are ratios rather than two independent knobs.

agreed with the distinction above. steady-state kinetics for a weekly dose with a week-long half-life are genuinely fairly forgiving of small day-to-day interval drift, that's part of why weekly dosing was viable as a format at all.

fair, my "lag" comment above is more mechanistic plausibility than a specific citation, want to be clear about that distinction

I think it's because the mechanism story is genuinely satisfying and easy to explain (smoother levels, fewer spikes) even though nobody's tested whether that translates into anything that matters clinically. A good story travels faster than an absent data point.

agreed it's under-studied relative to how much it matters, SURMOUNT-1 reported total body weight change, not composition, and I think that's true of most of the phase 3 program generally, which is exactly the gap this whole thread is pointing at

you're not missing anything, there genuinely isn't one published, which is part of why this whole community topic is so full of individual anecdote rather than settled practice

Good question and here is the actual reason rather than the reassurance.

The starting dose is a tolerability dose. Its job is to let your gut meet the drug gently. It is not expected to do much, and it was not expected to do much in the trials either.

On top of that, the half-life is around 168 hours, so it takes roughly four to five weeks of consistent dosing before you are at steady state on any given dose. At day 14 you are not yet at steady state on a dose that was never meant to produce an effect.

So: two independent reasons, both boring, both entirely expected. Your vial is almost certainly fine.

right, and that's kind of the whole argument for stretching it if your body's not cooperating — the trial pace optimised for trial length, not for any one person's stomach.

as someone who thinks about the biology side of this a lot: the mechanistic reality (appetite regulation returning to a prior set point once the drug effect fades) genuinely doesn't map well onto "relapse", which implies a choice or a slip. I'd support moving away from it, though I recognize changing community language is hard and slow.

that's a fair point and nobody in this thread suggested banning the word for self-description, just suggesting "regain" as the community's default framing rather than "relapse" as the assumed default

bit of both honestly. there's a real pharmacological piece — you're often still mid-titration around week 4-8, and the biggest satiety effects can lag the biggest dose increases by a couple weeks. but there's also a huge measurement-noise piece layered on top, and most people can't tell which one they're looking at.

Left up. It is careful about what is peptide and what is not, which is more than most threads here manage.

Left up, flair changed to Discussion. It is an opinion post and that is fine as long as it is labelled.

fibrosis improvement without worsening steatohepatitis is the phrase to learn

Retitled to distinguish preclinical from clinical, which the original ran together.

Accused the wrong party publicly and it was my storage. Correcting it here was the most uncomfortable post I have made and the right one.

Yes. Anyone reading this board should hold their conclusions loosely until phase 3 reports.

pharmacologically this also lines up with steady-state timing after a dose step, roughly makes sense that a later stall reflects the drug level itself having settled rather than early noise

the exception drug status route exists in several provinces

Chased the last three kilos with a dose increase and got a fortnight of constipation and no change in the number.

Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.

Same experience with the appetite effect being flatter across the week rather than front-loaded.

Independent result logged. There are almost none for this compound, so it is genuinely valuable.

FFMI is a ratio and it moves when either term moves

Right, and stopping for money reasons is not a failure of anything. It is a budget.